Page last updated: 2024-11-05

picloram

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Picloram: A picolinic acid derivative that is used as a herbicide. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

picloram : A pyridinemonocarboxylic acid that is pyridine-2-carboxylic acid which is substituted by a chloro group at positions 3,5 and 6, and by an amino group at position 4. It is a systemic herbicide used to control deeply rooted herbaceous weeds and woody plants in rights-of-way, forestry, range lands, pastures, and small grain crops. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID15965
CHEMBL ID461349
CHEBI ID34922
SCHEMBL ID13299
MeSH IDM0016836

Synonyms (99)

Synonym
AC-19878
piclorame
4-amino-3,5,6-trichlorpicolinsaeure
o7437x49dw ,
5-22-13-00585 (beilstein handbook reference)
unii-o7437x49dw
EN300-17244
4-aminotrichloropicolinic acid
atcp
tordon 10k
amdon
3,6-trichloro-4-aminopicolinic acid
nci-c00237
picloram
tordon 22k
k-pin
1918-02-1
nsc233899
4-amino-3,6-trichloro-2-picolinic acid
4-amino-3,6-trichloropicolinic acid
nsc-233899
wln: t6nj bvq cg dz eg fg
2-pyridinecarboxylic acid,5,6-trichloro-
picolinic acid,5,6-trichloro-
borolin
4-amino-3,6-trichlorpicolinsaeure
tordon
picloram, technical grade
2-pyridinecarboxylic acid, 4-amino-3,5,6-trichloro-
picolinic acid, 4-amino-3,5,6-trichloro-
4-amino-3,5,6-trichloropyridine-2-carboxylic acid
NCGC00091319-01
brn 0479075
epa pesticide chemical code 005101
hsdb 1151
ccris 520
einecs 217-636-1
3,5,6-trichloro-4-aminopicolinic acid
4-amino-3,5,6-trichloro-2-picolinic acid
2-pyridine carboxylic acid, 4-amino-3,5,6-trichloro-
4-amino-3,5,6-trichlorpicolinsaeure [german]
access
picloram [ansi:bsi:iso]
piclorame [iso-french]
grazon
nsc 233899
4-amino-3,5,6-trichloropicolinic acid
amdon grazon
4-amino-3,5,6-trichloro-2-pyridinecarboxylic acid
caswell no. 039
picloram, plant cell culture tested, bioreagent
NCGC00091319-03
NCGC00091319-02
STK179674
NCGC00091319-04
P1864
chebi:34922 ,
CHEMBL461349
AKOS000120784
NCGC00091319-07
NCGC00091319-06
NCGC00091319-05
NCGC00254950-01
cas-1918-02-1
tox21_301048
dtxcid101160
dtxsid1021160 ,
NCGC00258850-01
tox21_200043
NCGC00257597-01
tox21_201298
A813522
FT-0603577
F3055-0927
SCHEMBL13299
KS-5272
picloram [mi]
picloram [iarc]
picloram [iso]
picloram [hsdb]
SY023140
mfcd00012101
pathway
3,5,6-trichloro-4-amino-2-pyridinecarboxylic acid
picloram acid
4-amino-3,5,6-tri-chloropyridine-2-carboxylate
W-107725
chloramp (salt/mix)
picloram, pestanal(r), analytical standard
picloram 100 microg/ml in methanol
Z56899173
Q424662
AC1880
CS-0014129
HY-B2034
wom ,
picloram 200 microg/ml in methyl tert-butyl ether
picloram 100 ug/ml in methanol
picloram 200 microg/ml in methyl-tert. butyl ether

Research Excerpts

Overview

Picloram (PC) is a systemic herbicide that controls herbaceous weeds and woody plants. Picloram is a widely used chlorinated herbicide, which is quite persistent and mobile in soil and water.

ExcerptReferenceRelevance
"Picloram (PC) is a systemic herbicide that controls herbaceous weeds and woody plants. "( Picloram binds to the h1 and h4 helices of HSA domain IIIA at drug binding site 2.
Ahmad, A; Emerson I, A; Kanake, DW; Karn, R; Khan, JM; Sen, P, 2023
)
3.8
"Picloram is a widely used chlorinated herbicide, which is quite persistent and mobile in soil and water with adverse health and environmental risks. "( Highly sensitive fluorescence quantification of picloram using immunorecognition liposome.
Chen, LJ; Feng, CL; Huang, GH; Niu, CG; Pang, Y; Tang, L; Zeng, GM; Zhang, Y, 2010
)
2.06

Actions

Picloram at 450 μM promotes high callogenesis in leaf tissues of macaw palm, with a potential for somatic embryo formation. For picloram, K f was lower in the eroded (0.28 μmol L(1/n) kg(-1) as compared to the depositional Minnesota soil ( 0.75 μmol)

ExcerptReferenceRelevance
"Picloram at 450 μM promotes high callogenesis in leaf tissues of macaw palm, with a potential for somatic embryo formation."( Somatic embryogenesis from leaf tissues of macaw palm [Acrocomia aculeata (Jacq.) Lodd. ex Mart.].
Cardoso, IMAS; Luis, ZG; Meira, FS; Scherwinski-Pereira, JE, 2020
)
1.28
"For picloram, K f was lower in the eroded (0.28 μmol ((1-1/n)) L(1/n) kg(-1)) as compared to the depositional Minnesota soil (0.75 μmol ((1-1/n)) L(1/n) kg(-1))."( Comparative sorption, desorption and leaching potential of aminocyclopyrachlor and picloram.
Alonso, DG; Koskinen, WC; Oliveira, RS; Papiernik, SK, 2013
)
1.1

Treatment

ExcerptReferenceRelevance
"2. Treatment with picloram had little effect on epoxide hydratase and glutathione S-transferase activity, but caused a dose-dependent increase in ethoxyresorufin-O-deethylase activity and a concomitant decrease in aldrin epoxidase activity in male rats."( Effects of picloram on xenobiotic biotransformation in rat liver.
Reidy, GF; Rose, HA; Stacey, NH, 1987
)
0.99

Toxicity

Isothermal microcalorimetry was applied to study the toxic effects caused to microbial activity of a typical Brazilian agricultural soil. Bull trout were twofold more sensitive to picloram (30-day maximum acceptable toxic concentration of 0.1%).

ExcerptReferenceRelevance
" The acute oral LD50 was 950 mg/kg (812-1120) for males and 686 mg/kg (599-786) for females."( Acute, 14-day repeated dosing, and 90-day subchronic toxicity studies of potassium picloram.
Borzelleca, JF; Condie, LW; Hayes, JR, 1986
)
0.5
"The toxic effect of the herbicide picloram on the microbial population of a typical Brazilian red Latosol soil was studied in a series of microcalorimetric experiments."( Toxic effect caused on microflora of soil by pesticide picloram application.
Airoldi, C; Prado, AG, 2001
)
0.84
" Isothermal microcalorimetry was applied to study the toxic effects caused to microbial activity of a typical Brazilian agricultural soil by application of free and immobilized picloram."( A toxicity view of the pesticide picloram when immobilized onto a silica gel surface.
Airoldi, C; Prado, AG, 2003
)
0.79
"Due to rising concerns for environmental and human health, many toxic compounds, such as auxin-based herbicides, have been tested in relation their toxicity effect."( Searching an auxinic herbicide to use as positive control in toxicity assays.
Alves, TA; Clarindo, WR; Ferreira, A; Henrique, MKC; Pinheiro, PF; Praça-Fontes, MM; Roberto, CEO, 2021
)
0.62
" However, due to their persistence in aquatic environments, even at low concentrations, their use has been considered an environmental problem and caused concern regarding the adverse effects on human health."( Aqueous picloram degradation by hydroxyl radicals: Unveiling mechanism, kinetics, and ecotoxicity through experimental and theoretical approaches.
Carvalho-Silva, VH; Lastre-Acosta, AM; Ramos, B; Sanches-Neto, FO; Teixeira, ACSC, 2021
)
1.06

Bioavailability

The environmental mobility and bioavailability of Picloram (PCM) are determined by the amine and carboxylate chemical groups interaction with the soils mineral phases.

ExcerptReferenceRelevance
" In addition, picloram was poorly absorbed through human skin and it is unlikely that acutely toxic quantities will be absorbed by this route."( Pharmacokinetics of picloram in male volunteers.
Freshour, NL; Kastl, PE; Nolan, RJ; Saunders, JH, 1984
)
0.95
"The environmental mobility and bioavailability of Picloram (PCM) are determined by the amine and carboxylate chemical groups interaction with the soils mineral phases."( New insights on the structure of the picloram-montmorillonite surface complexes.
Afonso, Mdos S; Gaigneaux, EM; Marco-Brown, JL; Sánchez, RM; Trinelli, MA, 2015
)
0.94

Dosage Studied

Homozygous transgenic plants were resistant to at least 5 g of ai ha-1 picloram and grew normally to produce seed. wild-type plants did not survive.

ExcerptRelevanceReference
" The incidence of dead fetuses/resorptions and malformed fetuses (especially cleft palate) was increased in the highest dosage group."( Effects of gestational exposure to Tordon 202c on fetal growth and development in CD-1 mice.
Blakley, PM; Firneisz, GD; Kim, JS, 1989
)
0.28
" Fetal weight and crown-rump length were reduced in the highest dosage group."( Effects of paternal subacute exposure to Tordon 202c on fetal growth and development in CD-1 mice.
Blakley, PM; Firneisz, GD; Kim, JS, 1989
)
0.28
" A few isolated, sporadic cases of foetal malformations were observed in the dosed groups, but there was no indication of a dose-related embryotoxic or teratogenic response to treatment."( Teratological evaluation of picloram potassium salt in rabbits.
Jeffries, TK; John-Greene, JA; Johnson, KA; Ouellette, JH; Rao, KS, 1985
)
0.56
" Dose-response bioassays, using foliar application of picloram, showed that these homozygous transgenic plants were resistant to at least 5 g of ai ha-1 picloram and grew normally to produce seed, whereas wild-type plants did not survive."( Picloram resistance in transgenic tobacco expressing an anti-picloram scFv antibody is due to reduced translocation.
Hall, JC; Horsman, J; McLean, MD; Olea-Popelka, FC, 2007
)
2.03
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
herbicideA substance used to destroy plant pests.
synthetic auxinA synthetic compound exhibiting auxin activity.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
aminopyridineCompounds containing a pyridine skeleton substituted by one or more amine groups.
pyridinemonocarboxylic acidA monocarboxylic acid in which the carboxy group is attached to a pyridine (or substituted pyridine) ring.
chloropyridineCompounds containing a pyridine nucleus substituted with one or more chlorine atoms.
organochlorine pesticideAny organochlorine compound that has been used as a pesticide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency44.66840.004023.8416100.0000AID485290
RAR-related orphan receptor gammaMus musculus (house mouse)Potency28.14120.006038.004119,952.5996AID1159521
SMAD family member 2Homo sapiens (human)Potency18.91870.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency18.91870.173734.304761.8120AID1346859
AR proteinHomo sapiens (human)Potency8.10200.000221.22318,912.5098AID588515; AID743036; AID743053
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency59.96490.001022.650876.6163AID1224838; AID1224839; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency63.55030.000214.376460.0339AID720692
retinoid X nuclear receptor alphaHomo sapiens (human)Potency31.33710.000817.505159.3239AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.01990.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency61.73410.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency16.69580.000229.305416,493.5996AID1259244; AID588514; AID743069; AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency34.75450.001024.504861.6448AID588534; AID588535; AID743212
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency29.57650.023723.228263.5986AID743222; AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency45.64760.000723.06741,258.9301AID743085; AID743122
activating transcription factor 6Homo sapiens (human)Potency68.43220.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency6.099019.739145.978464.9432AID1159509
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00630.010039.53711,122.0200AID588545
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency25.08090.000323.4451159.6830AID743066
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency63.17230.000627.21521,122.0200AID651741; AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency19.92240.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency70.68750.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency19.92240.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (146)

TimeframeStudies, This Drug (%)All Drugs %
pre-199047 (32.19)18.7374
1990's14 (9.59)18.2507
2000's34 (23.29)29.6817
2010's37 (25.34)24.3611
2020's14 (9.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.17 (24.57)
Research Supply Index5.09 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index114.80 (26.88)
Search Engine Supply Index3.12 (0.95)

This Compound (47.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other159 (98.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]